Evidence map›Paper›PMID 35684482›Full record

ArticleMolecules (Basel, Switzerland)2022

Bicyclic Isoxazoline Derivatives: Synthesis and Evaluation of Biological Activity.

Kseniya N Sedenkova, Kristian S Andriasov, Marina G Eremenko, Yuri K Grishin, Vera A Alferova, Anna A Baranova, Nikolay A Zefirov, Olga N Zefirova, Vladimir V Zarubaev, Yulia A Gracheva and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. A Review of the Medicinal Importance and Perspectives of the 2-isoxazoline Scaffold.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025
    Review
  3. 3-[International journal of molecular sciences · 2023
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Kseniya N SedenkovaDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Kristian S AndriasovDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Marina G EremenkoDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Yuri K GrishinDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Vera A AlferovaGause Institute of New Antibiotics, B. Pirogovskaya 11, 119021 Moscow, Russia.ORCID 0000-0002-8961-5890
Anna A BaranovaGause Institute of New Antibiotics, B. Pirogovskaya 11, 119021 Moscow, Russia.
Nikolay A ZefirovDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Olga N ZefirovaDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Vladimir V ZarubaevSaint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, 14 Mira St., 197101 Saint Petersburg, Russia.ORCID 0000-0002-5224-3771
Yulia A GrachevaDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Elena R MilaevaDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Elena B AverinaDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Lomonosov Moscow State University · RUInstitute of Bioorganic Chemistry · RUSaint Petersburg Pasteur Institute · RU

Funding

The Ministry of Science and Higher Education of the Russian Federation Agreement with Zelinsky Institute of Organic Chemistry RAS No 075-15-2020-803
6 · The paper itself

Abstract

The application of non-planar scaffolds in drug design allows for the enlargement of the chemical space, and for the construction of molecules that have more effective target-ligand interactions or are less prone to the development of resistance. Among the works of the last decade, a literature search revealed spirothiazamenthane, which has served as a lead in the development of derivatives active against resistant viral strains. In this work, we studied the novel molecular scaffold, which resembles spirothiazamenthane, but combines isoxazoline as a heterocycle and cyclooctane ring as a hydrophobic part of the structure. The synthesis of new 3-nitro- and 3-aminoisoxazolines containing spiro-fused or 1,2-annelated cyclooctane fragments was achieved by employing 1,3-dipolar cycloaddition of 3-nitro-4,5-dihydroisoxazol-4-ol 2-oxide or tetranitromethane-derived alkyl nitronates with non-activated alkenes. A series of spiro-sulfonamides was obtained by the reaction of 3-aminoisoxazoline containing a spiro-fused cyclooctane residue with sulfonyl chlorides. Preliminary screening of the compounds for antiviral, antibacterial, antifungal and antiproliferative properties in vitro revealed 1-oxa-2-azaspiro[4.7]dodec-2-en-3-amine and 3a,4,5,6,7,8,9,9a-octahydrocycloocta[d]isoxazol-3-amine with activity against the influenza A/Puerto Rico/8/34 (H1N1) virus in the submicromolar range, and high values of selectivity index. Further study of the mechanism of the antiviral action of these compounds, and the synthesis of their analogues, is likely to identify new agents against resistant viral strains.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanAminesAntiviral AgentsCyclooctanesHumansStructure-Activity RelationshipAminesAntiviral AgentsCyclooctanesbicyclic compoundscyclooctanesheterocyclizationinfluenza A (H1N1)isoxazolinesspiro compounds

Identifiers

PMID35684482
PMCPMC9182378
OpenAlexW4281987781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.